Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl‐2 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Deliu, Zanë; Shergill, Ardaman; Meier, Anne; Myint, Phyo Thazin; Khan, Sarah; Khosla, Paramjeet; Feldman, Lawrence E.

doi:10.1002/9781119432487.ch4

Cited by 2 publications

(2 citation statements)

References 219 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…73 Moreover, it has been claimed that the over-expression in the EGFR gene not only resulted in the advanced stage of the disease 74,75 but also negatively affected the response rate of HNSCC cells to surgery, chemotherapy, and radiation. 76 In an interesting study, the results of high-F I G U R E 2 A summary of mutations in the EGFR and components of the PI3K/Akt/ mTOR pathway in HNSCC. Thus far, several genetic alteration in different components of the PI3K/Akt signaling axis in HNSCC patients has been identified.…”

Section: Hnscc In a Prospective Of Genetic Alterations In The Pi3k Axismentioning

confidence: 99%

“…Chung et al revealed that those HNSCC patients who were positive for EGFR gene amplification had worse progression‐free and overall survival 73 . Moreover, it has been claimed that the over‐expression in the EGFR gene not only resulted in the advanced stage of the disease 74,75 but also negatively affected the response rate of HNSCC cells to surgery, chemotherapy, and radiation 76 . In an interesting study, the results of high‐resolution global copy number and mutational analysis of the EGFR pathway revealed that some other mediatory proteins that are involved in the regulation of this protein, such as protein tyrosine phosphatase receptor S (PTPRS) could also undergo genetic alterations.…”

Section: Hnscc In a Prospective Of Genetic Alterations In The Pi3k Axismentioning

confidence: 99%

See 1 more Smart Citation

The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies

Dilmaghani

Safaroghli‐Azar

Pourbagheri‐Sigaroodi

et al. 2021

IUBMB Life

View full text Add to dashboard Cite

The latest advances in the sequencing methods in head and neck squamous cell carcinoma (HNSCC) tissues have revolutionized our understanding of the disease by taking off the veil from the most frequent genetic alterations in the components of the oncogenic pathways. Among all the identified alterations, aberrancies in the genes attributed to the phosphoinositide 3-kinases (PI3K) axis have attracted special attention as they were altered in more than 90% of the tissues isolated from HNSCC patients. In fact, the association between these aberrancies and the increased risk of cancer metastasis suggested this axis as an "Achilles Heel" of HNSCC, which may be therapeutically targeted. The results of the clinical trials investigating the therapeutic potential of the inhibitors targeting the components of the PI3K axis in the treatment of HNSCC patients, either alone or in a combined-modal strategy, opened a new chapter in the treatment strategy of this malignancy. The present study aimed

show abstract

Section: Hnscc In a Prospective Of Genetic Alterations In The Pi3k Axismentioning

confidence: 99%

Section: Hnscc In a Prospective Of Genetic Alterations In The Pi3k Axismentioning

confidence: 99%

The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies

Dilmaghani

Safaroghli‐Azar

Pourbagheri‐Sigaroodi

et al. 2021

IUBMB Life

View full text Add to dashboard Cite

show abstract

Assessment of MicroRNA-15a and MicroRNA-16-1 Salivary Level in Oral Squamous Cell Carcinoma Patients

Koopaie

Manifar

Lahiji

2021

MIRNA

View full text Add to dashboard Cite

Background: Squamous Cell Carcinoma (SCC) includes more than 90% of malignancies of the oral cavity. Early diagnosis could effectively improve patients' quality of life and treatment outcomes of oral cancers. MicroRNAs as non-encoding genes have great potential to initiate or suppress cancer progression. Recent studies have shown that disruption of micro-RNA regulation is a common occurrence in cancers. Objective: This study set out to evaluate the expression of microRNA-15a (miR-15a) and microRNA-16-1 (miR-16-1) in the saliva of Oral Squamous Cell Carcinoma (OSCC) patients in comparison with a healthy control group. Methods: This case-control study was performed on fifteen patients with OSCC and fifteen healthy volunteers as the control group. A 5 ml of non-stimulating whole saliva was collected by spitting method from patients and controls and stored at -70oC. The expression of miR-15a and miR-16-1 was investigated using quantitative Reverse-Transcription Polymerase Chain Reaction (RT-qPCR). Results: MiR-15a and miR-16-1 were downregulated in OSCC patients compared with the control group (p<0.001). The sensitivity of miR-15a and miR-16-1 in differentiating OSCC patients from healthy individuals was 93.3% and 86.67%, respectively, and their specificity was 86.67% and 92.33%, respectively. The diagnostic accuracy of miR-15a was 90%, and miR-16-1 was 93.3%. Conclusion: The present study showed a decrease in the relative expression of miR-15a and miR-16-1 in OSCC patients compared with healthy individuals. It is probable to introduce salivary values of miR-15a and miR-16-1 as a non-invasive tool for early detection of OSCC. Decreased expression of miR-15a and miR-16-1 in OSCC indicates the possible effective role of these genes in OSCC etiopathogenesis.

show abstract

Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl‐2 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Cited by 2 publications

References 219 publications

The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies

The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies

Assessment of MicroRNA-15a and MicroRNA-16-1 Salivary Level in Oral Squamous Cell Carcinoma Patients

Contact Info

Product

Resources

About